Selpercatinib: Dosing and Administration Essentials of an Oral RET Inhibitor

    　Before Starting:Genetic Testing Comes First

　　Selpercatinib is an oral RET-targeted agent whose use rests on molecular selection.Treatment decisions are guided by genetic testing of tumor tissue:patients with RET fusion–positive non-small cell lung cancer(NSCLC),thyroid cancer or other RET fusion–positive solid tumors,as well as those with medullary thyroid cancer harboring specific RET mutations,must have their eligibility confirmed by the corresponding test results.

　　Weight-Based Daily Dosing

　　The recommended dose is determined by body weight.For patients weighing less than 50 kg,the recommended dose is 120 mg orally twice daily;for those weighing 50 kg or more,it is 160 mg orally twice daily.Doses are spaced roughly 12 hours apart,and treatment is generally continued until disease progression or unacceptable toxicity.

　　Food and Acid-Reducing Agents

　　Selpercatinib may be taken with or without food.Because gastric pH affects its absorption,however,coadministration with acid-reducing agents calls for care:when a proton pump inhibitor(PPI)is used,selpercatinib should be taken with food as specified in the labeling.With H2 receptor antagonists or antacids,an appropriate interval between doses should be maintained to limit the impact of altered gastric acidity on absorption.

　　Vomiting and Missed Doses

　　If vomiting occurs after a dose is taken,an additional dose should not be administered;the patient should simply take the next dose at its scheduled time.Capsules or tablets should be swallowed whole as directed,and neither the daily frequency nor the individual dose should be changed without medical guidance.

　　Individualization and Key Takeaways

　　In practice,doses may be modified in response to adverse reactions,hepatic impairment,or drug–drug interactions.Selpercatinib is a RET inhibitor that must be taken consistently and on schedule;getting the daily dose,the dosing interval,and the relationship with acid-reducing agents right is central to both efficacy and safety.The prescribing information for the specific product and the prescribing physician's plan remain the final authority.